QN-165 is under clinical development by Qualigen Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect QN-165’s likelihood of approval (LoA) and phase transition for Pancreatic Cancer took place on 24 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their QN-165 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

QN-165 overview

QN-165 is under development for the treatment of acute myelocytic leukemia, pancreatic cancer. It is administered through intravenous route. It is a 26-base guanine-rich oligodeoxynucleotide aptamer which acts by targeting nucleolin protein. It was also under development for the treatment of solid tumors, metastatic renal cell carcinoma, coronavirus COVID-19 disease.

Qualigen Therapeutics overview

Qualigen Therapeutics (Qualigen) develops therapeutics for the treatment of cancer and infectious diseases. The Company’s cancer therapeutics pipeline includes QN-247, RAS-F and STARS. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. QN-247 is a nanoparticle coating technology that is similar to the core nanoparticle coating technology used in blood-testing diagnostic products. QN-165 is a drug candidate for treating viral-based infectious diseases. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing binding tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen is headquartered in Los Angeles, California, the US.

Quick View QN-165 LOA Data

Report Segments
  • Innovator
Drug Name
  • QN-165
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.